JPM CBRN Medical TechWatch

Advancing CBRN Defense Through JPEO Partnership

On November 9, 2023, Model Medicines presented our industry-leading AI drug discovery platform GALILEO and lead pan-antiviral asset MDL-001 to the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND).
The JPEO-CBRND oversees critical efforts to equip and protect U.S. forces against CBRN and emerging threats.
Our discussion focused on:

• Model's threat-agnostic approach to discovering countermeasures

• The ability of our platform to rapidly respond to capability gaps

• MDL-001's potential as a versatile medical countermeasure

• Partnership opportunities across JPEO-CBRND programs

We appreciated the productive dialogue on developing flexible solutions aligned with JPEO-CBRND's mission.
Model Medicines remains committed to working with key stakeholders across defense and government to ensure preparedness and effective response to health security threats.

To learn more about our JPEO-CBRND presentation or partnership opportunities, visit our website at www.modelmedicines.com/investors or contact us.